Program
GENSCI128
A development code. Also written as “GenSci128 tablets”.
Its studies are led by Changchun GeneScience Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | 11 open or running | phase 1since Mar 19, 2025 | Mar 19, 2025 | Dec 2027phase 1 · NCT06908434 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 19, 2025First study: phase 1 study in Solid Tumors Harboring a TP53 Y220C MutationFirst studyNCT06908434 · 82 planned · China
Ahead
- Dec 2027Primary completion: phase 1 study in Solid Tumors Harboring a TP53 Y220C MutationNCT06908434
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06908434Solid Tumors Harboring a TP53 Y220C Mutation · China | 1 | Recruiting | Dec 2027 | 82 |
How it is read
Names in the registry
- “GenSci128 tablets”, 1 entry
Codes read as this program: GENSCI128.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.